PRESENTATION
Q4 2020 — Results presentation
Q4 2020PDF · 38 pages3.2 MB
1 -- 1 of 38 -- 4th Quarter 2020 Earnings Call January 26, 2021 -- 2 of 38 -- Cautionary Note on Forward-looking Statements 3 This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to our business, or on our ability to execute business continuity plans, as a result of the COVID-19 pandemic; economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the company’s most recently filed Quarterly Report on Form 10-Q and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Cautionary Note on Non-GAAP Financial Measures This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company’s website at www.investor.jnj.com. -- 3 of 38 -- Strategic Partnerships, Collaborations & Licensing Arrangements 4 During the course of this morning’s presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships: Immunology REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation, and TREMFYA discovered using MorphoSys AG antibody technology Neuroscience INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA includes technology licensed from Alkermes Pharma Ireland Limited, RISPERDAL CONSTA developed in collaboration with Alkermes, Inc. Infectious Diseases PREZCOBIX/ REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with ViiV Healthcare UK Cardiovascular/ Metabolism/Other INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation, XARELTO co-developed with Bayer HealthCare AG, PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx Oncology IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company, ZYTIGA licensed from BTG International Ltd., VELCADE developed in collaboration with Millennium: The Takeda Oncology Company, DARZALEX licensed from Genmab A/S, BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc., and cusatuzumab licensed and developing in collaboration argenx BVBA and argenx SE, ERLEADA is licensed from Regents of California and Memorial Sloan Kettering, BCMA CAR-T licensed and developed in collaboration with Legend Biotech USA Inc., Legend Biotech Ireland Limited (“Legend”), subsidiaries of GenScript Biotech Corporation, niraparib licensed from TESARO, Inc., an oncology-focused business within GSK, and DuoBody platform licensed from Genmab relates to several bispecific antibody programs; ENHANZE platform licensed from Halozyme Therapeutics, Inc. Pulmonary Hypertension UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan Global Public Health Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by the BARDA, within the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C.. The initial work on Ebola was conducted which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center (VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C -- 4 of 38 -- Enterprise Highlights Sales Performance and Earnings Review Capital Allocation and Guidance Q&A 5 Agenda 1 2 3 4 Joseph J. Wolk Executive Vice President, Chief Financial Officer Chris DelOrefice Vice President, Investor Relations Alex Gorsky Chairman and Chief Executive Officer -- 5 of 38 -- Alex Gorsky Chairman and Chief Executive Officer 4TH QUARTER 2020 EARNINGS -- 6 of 38 -- -- 7 of 38 -- Good health is pivotal to our safety, security and prosperity as a society. -- 8 of 38 -- 9 -- 9 of 38 -- People Innovation Execution 10 -- 10 of 38 -- 28 Platforms/Products with over $1B in Annual Sales in 2020 $2B+ Platforms/Products (12) $1B+ Platforms/Products (16) *Sales > $1B adjusted for the estimated impact of COVID-19 in 2020 Note: SIMPONI Includes SIMPONI and SIMPONI ARIA; PREZISTA includes PREZISTA AND PREZCOBIX 11 Trauma Wound Closure Electrophysiology Contact Lens Biosurgicals Vision Surgical* Energy Endocutters Hips Knees Spine * Execution -- 11 of 38 -- Unparalleled scientific expertise allows us to create life enhancing innovation. Innovation -- 12 of 38 -- 13 We are powered by our people, purpose and values system. People -- 13 of 38 -- -- 14 of 38 -- Regional Sales Results Q4 2020 Q4 2019 % CHANGE Reported Operational1 U.S. $11.8 $10.8 9.6% 9.6% Europe 5.3 4.7 13.0 7.7 Western Hemisphere (ex U.S.) 1.4 1.5 (6.1) 2.9 Asia-Pacific, Africa 4.0 3.8 4.6 0.7 International 10.7 10.0 7.0 4.3 Worldwide (WW) $22.5 $20.7 8.3% 7.1% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Note: Values may not add due to rounding 4th Quarter 2020 Sales Dollars in Billions 15 -- 15 of 38 -- (1.1)%; (3.2)%1 Q4 2020 Q4 2019 $1.86 $1.88 4th Quarter 2020 Financial Highlights Dollars in Billions, except EPS Reported %; Operational %1 16 Sales Adjusted Earnings2 Adjusted EPS2 8.3%; 7.1%1 $22.5 $20.7 GAAP Earnings (56.7)% $1.7 $4.0 (1.2)% Q4 2020 Q4 2019 GAAP EPS (56.7)% $0.65 $1.50 Q4 2020 Q4 2020 Q4 2019 Q4 2019 Q4 2020 Q4 2019 $5.0 $5.0 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website -- 16 of 38 -- Regional Sales Results 2020 2019 % CHANGE Reported Operational1 U.S. $43.1 $42.1 2.5% 2.5% Europe 19.0 18.5 2.8 2.0 Western Hemisphere (ex U.S.) 5.3 5.9 (10.2) 0.4 Asia-Pacific, Africa 15.1 15.6 (2.7) (3.1) International 39.5 40.0 (1.3) (0.2) Worldwide (WW) $82.6 $82.1 0.6% 1.2% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Note: Values may not add due to rounding Full Year 2020 Sales Dollars in Billions 17 -- 17 of 38 -- (7.5)%; (7.8)%1 2020 2019 $8.03 $8.68 Full Year 2020 Financial Highlights Dollars in Billions, except EPS Reported %; Operational %1 18 Sales Adjusted Earnings2 Adjusted EPS2 0.6%; 1.2%1 $82.6 $82.1 GAAP Earnings (2.7)% $14.7 $15.1 (8.1)% 2020 2019 GAAP EPS (2.1)% $5.51 $5.63 2020 2020 2019 2019 2020 2019 $21.4 $23.3 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website -- 18 of 38 -- OTC $1,185 Skin Health/Beauty $1,177 Oral Care $437 Baby Care $407 Women's Health $237 Wound Care/Other $175 $3,618 1.4%, 2.0% WW Sales $MM ■ Reported Growth ■ Operational Growth1 Consumer Health Highlights – 4th Quarter 2020 Solid performance driven by Oral Care, Wound Care and recovery in Skin Health/Beauty 19 Key Drivers of Operational Performance1 OTC • U.S. flat due to share and e-commerce/club channel growth across multiple brands including TYLENOL in pain primarily driven by COVID-19 demand, PEPCID due to competitive withdrawal, and ZYRTEC due to competitive out-of-stock offset by category declines due to lower cough/cold/flu incidences attributed to COVID-19 restrictions and lapping prior year stocking • OUS decline due to COVID-19 negative impacts driven by restrictions resulting in lower cough and flu incidences partially offset by increased consumption in anti-smoking aids in EMEA, Children's MOTRIN in China and Adult TYLENOL in Canada Skin Health/ Beauty • U.S. growth driven by e-commerce and club channel across several brands, OGx and MAUI MOISTURE share gains mostly offset by COVID-19 related market declines coupled with competitive pressures • OUS growth driven by Dr. CI LABO, NEUTROGENA, OGx and AVEENO due to e-commerce and innovations. Results were partially offset by lower consumption, and COVID-19 impacts in JOHNSON's Adult in EMEA Oral Care • Growth primarily due to LISTERINE mouthwash share gains driven by strong e- commerce and club channel performance, mouthwash category growth related to increased COVID-19 demand and new product offerings in APAC Baby Care • U.S. growth due to JOHNSON's and AVEENO e-commerce growth driven by COVID-19 demand and increased retailer stocking • OUS decline due to SKU rationalization and the negative impact of COVID-19 partially offset by growth in AVEENO baby Women’s Health • Declines driven by liners and internal sanitary protection driven by COVID-19 impacts across all regions partially offset by growth in napkins in APAC Wound Care/Other • Share and market growth in e-commerce in NEOSPORIN and BAND-AID® Brand Adhesive bandages primarily attributed to elevated COVID-19 demand Adjusted Operational Sales2: WW 2.1%, U.S. 2.8%, Int’l 1.6% Additional shipping days contributed ~4% to WW growth Reported: WW 1.4%, U.S. 2.7%, Int’l 0.5% Operational1: WW 2.0%, U.S. 2.7%, Int’l 1.5% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding (0.8)%, (1.5)% (6.3)%, (2.9)% 12.0%, 12.2% (3.4)%, 0.0% 11.4%, 12.0% 2.4%, 2.6% -- 19 of 38 -- Key Drivers of Operational Performance1 Immunology • Growth driven by strong uptake of STELARA in Crohn’s Disease and Ulcerative Colitis, strength of TREMFYA in Psoriasis and uptake in Psoriatic Arthritis, and volume/share gains in SIMPONI ARIA • REMICADE decline due to increased discounts/rebates and biosimilar competition Infectious Diseases • Growth driven by strong sales of SYMTUZA in the U.S. and uptake of JULUCA in the EU, partially offset by increased competition for PREZISTA/PREZCOBIX/REZOLSTA and PREZISTA OUS LOE Neuroscience • Paliperidone long-acting injectables growth due to strength of INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA from new patient starts and persistency Oncology • DARZALEX increase driven by continued strong market growth and share gains in all regions and solid uptake of the subcutaneous formulation that was approved in the U.S. and EU in Q2 • Strong sales of IMBRUVICA due to market growth/leadership position in the U.S. and increased patient uptake outside the U.S. • Continued strong global launch uptake of ERLEADA • Lower sales and share of VELCADE and U.S. ZYTIGA due to generic competition Cardiovascular/ Metabolism/ Other (CVM/Other) • Decline driven by lower sales of PROCRIT/EPREX due to biosimilar competition • Modest growth in XARELTO due to demand growth, partially offset by increased rebates • INVOKANA/INVOKAMET increase due to market growth and favorable channel mix in the U.S., as well as strength in the EU, partially offset by U.S. share declines due to competitive pressures Pulmonary Hypertension (PH) • Growth driven by strong sales of OPSUMIT and UPTRAVI due to continued share gains, market growth, and the favorable impact of a distributor model change that took place in the U.S. in Q4 2019 Adjusted Operational Sales2: WW 14.6%, U.S. 15.2%, Int’l 13.7% Additional shipping days contributed ~4% to WW growth Immunology $4,105 Infectious Diseases $912 Neuroscience $1,698 Oncology $3,434 CVM/Other $1,253 PH $865 $12,268 16.3%, 14.6% WW Sales $MM ■ Reported Growth ■ Operational Growth1 Pharmaceutical Highlights – 4th Quarter 2020 20 Reported: WW 16.3%, U.S. 15.3%, Int’l 17.7% Operational1: WW 14.6%, U.S. 15.3%, Int’l 13.5% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding (0.2)%, (1.0)% 39.0%, 37.4% 26.4%, 23.7% 8.5%, 7.0% 5.4%, 2.7% 16.6%, 15.3% Robust above-market performance driven by double-digit growth in 8 key products -- 20 of 38 -- Orthopaedics $2,191 Surgery $2,429 Vision $1,076 Interventional Solutions $893 $6,589 (0.7)%, (2.2)% WW Sales $MM ■ Reported Growth ■ Operational Growth1 Medical Devices Highlights – 4th Quarter 2020 Decline driven by negative impact of COVID-19, partially offset by double digit growth in Interventional Solutions 21 Reported: WW (0.7)%, U.S. 1.5%, Int’l (2.6)% Operational1: WW (2.2)%, U.S. 1.5%, Int’l (5.5)% Key Drivers of Operational Performance1 Interventional Solutions • Double-digit growth driven by atrial fibrillation procedure growth coupled with strength from new products including CARTO and VIZIGO sheath Orthopaedics • Hips: Primarily driven by the negative impact of COVID-19 partially offset by leadership in the Anterior approach and strong market demand for the ACTIS stem and enabling technologies – KINCISE and VELYS Hip Navigation • Trauma: U.S. market recovery and global success from new products offsetting impact of COVID-19 on OUS markets and stocking reductions in China. • Knees: Decline driven by the negative impact of COVID-19 • Spine, Sports & Other: Negative impact from COVID-19 and stocking reductions in China partially offset by uptake of new products in Spine • Spine: WW: ~(7)%, U.S.: ~+2%, OUS: ~(20)% Surgery • Advanced: • Endocutters: ~+2% Driven by new products, primarily in EMEA and China • Biosurgery: ~+6% Led by share gains from SURGIFLO after prior year supply disruption in the U.S. • Energy: ~(3)% Primarily driven by the negative impact of COVID-19 and competitive pressures in the U.S. partially offset by new product growth in China • General: Decline primarily due to negative impact of COVID-19, partially offset by global breast implant market recovery and increase in Wound Closure stock in the U.S. Vision • Contact Lenses/Other: Decline primarily driven by the negative impact COVID-19 and reduced stocking in the U.S. • Surgical: Decline primarily driven by the negative impact of COVID-19 Adjusted Operational Sales2: WW (1.5)%, U.S. 1.7%, Int’l (4.4)% Additional shipping days contributed ~4% to WW growth 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding 15.3%, 12.8% (5.7)%, (6.6)% (3.7)%, (5.3)% (0.5)%, (1.9)% -- 21 of 38 -- Condensed Consolidated Statement of Earnings 1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 22 2020 2019 % Increase (Decrease) Amount % to Sales Amount % to Sales Sales to customers $22,475 100.0 $20,747 100.0 8.3 Cost of products sold 7,814 34.8 7,134 34.4 9.5 Gross Profit 14,661 65.2 13,613 65.6 7.7 Selling, marketing, and administrative expenses 6,457 28.7 6,039 29.1 6.9 Research and development expense 4,032 17.9 3,232 15.6 24.8 In-process research and development 37 0.2 - - Interest (income) expense, net 74 0.3 4 0.0 Other (income) expense, net 2,354 10.5 16 0.1 Restructuring 60 0.3 104 0.5 Earnings before provision for taxes on income 1,647 7.3 4,218 20.3 (61.0) Provision for / (Benefit from) taxes on income (91) (0.4) 208 1.0 (143.8) Net Earnings $1,738 7.7 $4,010 19.3 (56.7) - Net earnings per share (Diluted) $0.65 $1.50 (56.7) Average shares outstanding (Diluted) 2,669.2 2,669.1 Effective tax rate (5.5)% 4.9% . Adjusted earnings before provision for taxes and net earnings1 Earnings before provision for taxes on income $5,601 24.9 $5,628 27.1 (0.5) Net earnings $4,965 22.1 $5,027 24.2 (1.2) Net earnings per share (Diluted) $1.86 $1.88 (1.1) Effective tax rate 11.4% 10.7% 4th Quarter 2020 (Unaudited; Dollar and Shares in Millions Except Per Share Figures) -- 22 of 38 -- 2020 2019 ($0.3) ($0.3) Adjusted Income Before Tax by Segment1 4th Quarter 2020 $5.6B $4.0 $1.1 23 Pharmaceutical Medical Devices Consumer Health Expenses Not Allocated to Segments 4Q 2020 4Q 2019 Pharmaceutical 32.9% 33.8% Medical Devices 16.5% 25.5% Consumer Health 22.5% 18.2% Total 24.9% 27.1% 1 Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 2 Estimated as of 1/26/2021 $5.6B $3.6 $1.7 $0.6 % to Sales 2 $0.8 -- 23 of 38 -- Condensed Consolidated Statement of Earnings 1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 24 2020 2019 % Increase (Decrease) Amount % to Sales Amount % to Sales Sales to customers $82,584 100.0 $82,059 100.0 0.6 Cost of products sold 28,427 34.4 27,556 33.6 3.2 Gross Profit 54,157 65.6 54,503 66.4 (0.6) Selling, marketing, and administrative expenses 22,084 26.8 22,178 27.0 (0.4) Research and development expense 12,159 14.7 11,355 13.8 7.1 In-process research and development 181 0.2 890 1.1 Interest (income) expense, net 90 0.1 (39) 0.0 Other (income) expense, net 2,899 3.5 2,525 3.1 Restructuring 247 0.3 266 0.3 Earnings before provision for taxes on income 16,497 20.0 17,328 21.1 (4.8) Provision for taxes on income 1,783 2.2 2,209 2.7 (19.3) Net Earnings $14,714 17.8 $15,119 18.4 (2.7) - Net earnings per share (Diluted) $5.51 $5.63 (2.1) Average shares outstanding (Diluted) 2,670.7 2,684.3 Effective tax rate 10.8% 12.7% . Adjusted earnings before provision for taxes and net earnings1 Earnings before provision for taxes on income $25,428 30.8 $28,225 34.4 (9.9) Net earnings $21,433 26.0 $23,310 28.4 (8.1) Net earnings per share (Diluted) $8.03 $8.68 (7.5) Effective tax rate 15.7% 17.4% Full Year 2020 (Unaudited; Dollar and Shares in Millions Except Per Share Figures) -- 24 of 38 -- 2020 2019 ($0.9) ($0.8) Adjusted Income Before Tax by Segment1 Full Year 2020 $25.4B $19.1 $3.9 $3.3 25 Pharmaceutical Medical Devices* Consumer Health Expenses Not Allocated to Segments YTD 2020 YTD 2019 Pharmaceutical 42.0% 40.0% Medical Devices 17.0% 35.4% Consumer Health 23.8% 21.4% Total 30.8% 34.4% 1 Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 2 Estimated as of 1/26/2021 $28.2B $16.9 $9.2 $3.0 % to Sales 2 * 2019 includes approximately $2.0 billion related to the divestiture of the Advanced Sterilization Products (ASP) business. -- 25 of 38 -- Notable New Announcements in 4th Quarter 20201 Pharmaceuticals • Regulatory Approvals: – DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) - Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis2 – CABENUVA (rilpivirine/cabotegravir) - U.S. FDA Approval and European Commission Authorization of the first complete long acting injectable HIV treatment2 – TREMFYA (guselkumab) - European Commission Approves First-in-Class treatment for Active Psoriatic Arthritis (PsA) • Regulatory Submissions: – Amivantamab - Submission of U.S. FDA and European Marketing Authorization Application for Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations – BCMA CAR-T Therapy (ciltacabtagene autoleucel) - Rolling Submission of a Biologics License Application to U.S. FDA for the Treatment of Relapsed and/or Refractory Multiple Myeloma – DARZALEX (daratumumab and hyaluronidase-fihj) - Janssen Submits Applications in U.S. and EU Seeking Approval of DARZALEX FASPRO (daratumumab and hyaluronidase- fihj)/DARZALEX (daratumumab) Subcutaneous (SC) Formulation in Combination With Pomalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma – Paliperidone Palmitate 6-Month - Submission of Supplemental New Drug Application to U.S. FDA and European Marketing Authorization for Treatment of Schizophrenia in Adults – XARELTO (rivaroxaban) - Submission of Application to U.S. FDA for New Indication to Expand Use in Patients with Peripheral Artery Disease • Other: – Janssen Receives Positive CHMP Opinion for SPRAVATO (esketamine Nasal Spray) for the Rapid Reduction of Depressive Symptoms in a Psychiatric Emergency for Patients with Major Depressive Disorder – Janssen Acquires Rights to Novel Gene Therapy, Pioneering Treatment Solutions for Late-Stage Age-Related Macular Degeneration – Johnson & Johnson Initiates Second Global Phase 3 Clinical Trial of its Janssen COVID-19 Vaccine Candidate Medical Devices • Regulatory Approvals: – VELYS Robotic-Assisted Solution- Receives 510(k) FDA Clearance Designed for Use with the ATTUNE Total Knee System2 26 1 These developments and all other news releases are available online in the Investors section of the company’s website at news releases 2 Subsequent to the quarter -- 26 of 38 -- Business Review …Highlighting Pharmaceutical Pipeline and Capabilities Thursday, November 18, 2021 Save the Date -- 27 of 38 -- Joseph J. Wolk Executive Vice President, Chief Financial Officer -- 28 of 38 -- Capital Allocation Strategy Capital Allocation Organic growth business needs Free cash flow1 Priorities are clear and remain unchanged Competitive dividends Share repurchases HIGHER PRIORITY LOWER PRIORITY Investment in M&A Dollars in Billions Q4 2020 Cash and Marketable Securities $25.0 Debt ($35.0) Net Debt ($10.0) Free Cash Flow2 ~$20.0 2020: $12.2B invested in R&D $10.5B in dividends paid to shareholders Note: values may have been rounded 1 Non-GAAP measure; cash flow from operations less CAPEX 2 Estimated as of January 26, 2021 29 -- 29 of 38 -- 30 2021 Sales Guidance January Comments Adjusted Operational Sales1,2 8.0% - 9.5% Midpoint of 8.8% Operational Sales2 $88.8B - $90.0B 7.5% – 9.0% Net Impact Acq./Div: ~-0.5% Estimated Reported Sales 3 $90.5B - $91.7B 9.5% – 11.0% FX $1.7B or +2.0% impact Assumptions and Outlook • Tax based on current regulations • Pharm net price decreases similar to recent trends • Stabilization of unemployment levels • Reduced levels of COVID-19 restrictions; procedures largely permissible throughout year 1 Non-GAAP measure; excludes acquisitions and divestitures 2 Non-GAAP measure; excludes the impact of translational currency 3 Euro Average Rate: January 2021 = $1.21 -- 30 of 38 -- 31 2021 EPS Guidance1 Adjusted Reported3,4 Adjusted Operational2,4 ~ ~ ~ 1 Represents the midpoint of guidance 2 Excludes the impact of translational currency 3 Euro Average Rate: January 2021 = $1.21 4 Non-GAAP measure; excludes intangible amortization expense and special items $8.03 ~ 2020 Adjusted Reported EPS Sales Ops Growth Momenta Dilution Net Income Margin Improvement 2021 Adjusted Operational EPS 2021 Adjusted Reported EPS Currency3 $9.25 - $9.45 15.2% - 17.7% $9.40 - $9.60 17.1% - 19.6% $9.35 $9.50 -- 31 of 38 -- 2021 Guidance 1 Non-GAAP measure; excludes acquisitions and divestitures 4 Non-GAAP measure; excludes intangible amortization expense and special items 2 Non-GAAP measure; excludes the impact of translational currency 5 Sales less: COGS, SM&A and R&D expenses 3 Euro Average Rate: January 2021 = $1.21 32 January Comments Adjusted Operational Sales1,2 8.0% - 9.5% Midpoint of 8.8% Operational Sales2 $88.8B - $90.0B 7.5% – 9.0% Net Impact Acq./Div: ~-0.5% Estimated Reported Sales 3 $90.5B - $91.7B 9.5% – 11.0% FX $1.7B or +2.0% impact Adjusted Pre-Tax Operating Margin4,5 >200 bps improvement Sales leverage including MD procedure recovery and cost improvement initiatives Net Other Income4 $0.6 - $0.7 billion Normalized levels Net Interest Expense / (Income) $150 - $250 million Assumes no major acquisitions or other major uses of cash Effective Tax Rate4 16.5% - 17.5% One-time benefit items in 2020 related to the close out of audits Adjusted EPS (Operational)2,4 $9.25 - $9.45 15.2% - 17.7% Midpoint of $9.35 or 16.4% Adjusted EPS (Reported)3,4 $9.40 - $9.60 17.1% - 19.6% Midpoint of $9.50 or 18.3% FX $0.15 or +1.9% impact -- 32 of 38 -- 2021 Segment Outlook & Quarterly Sales Phasing* *Chart is not to scale; Illustration intended to visualize quarterly phasing impact of operational sales growth rates throughout 2021 Q1 2021 Q2 2021 2H 2021 Enterprise Pharmaceutical Medical Devices Consumer Health Segment Full Year Considerations Quarterly Sales Phasing and Considerations Pharmaceutical Continued strong, above market performance • Anticipate more balanced quarter to quarter growth throughout 2021 • First quarter prior year comp. included ~200 BPS favorable impact of longer terms script durations and upside due to one-time favorable prior period adjustments • Prior year included some negative impacts from reduced office visits and access to physician administered drugs due to COVID-19 restrictions most prominent in Q2 and reduced through the remaining quarters of 2020 Medical Devices Double digit growth driven by procedure recovery and continued momentum from new product introductions • Tempered growth in first quarter with anticipation of continued, moderate procedural disruption • Expect highest growth rate in second quarter given prior year market disruption and 2021 recovery • Expect continued market recovery and strengthened core platforms to drive revenue growth through 2021 Consumer Health Continue to drive competitive market growth • Negative impact to first quarter sales driven by enhanced COVID-19 demand comparisons primarily in OTC products • Continued SKU rationalization program negative impact to first half growth • Anticipate normalized growth in the second half as consumers return to typical usage patterns in areas like Skin Health / Beauty Note: Fourth Quarter growth will be negatively impacted by additional 2020 selling days that will not be repeated in 2021 (Q4 2020: ~4pts of growth related to additional selling days) Operational Sales Growth vs. 2020 33 Illustration intended to visualize quarterly phasing; Chart not to scale -- 33 of 38 -- Q&A Joseph J. Wolk Executive Vice President, Chief Financial Officer Chris DelOrefice Vice President, Investor Relations Chairman and Chief Executive Officer Alex Gorsky -- 34 of 38 -- -- 35 of 38 -- OTC $4,824 Skin Health/Beauty $4,450 Oral Care $1,641 Baby Care $1,517 Women's Health $901 Wound Care/Other $720 $14,053 1.1%, 3.0% WW Sales $MM ■ Reported Growth ■ Operational Growth1 (3.1)%, (2.0)% 7.4%, 9.7% (9.4)%, (4.9)% (8.6)%, (2.7)% 7.2%, 8.3% Consumer Health Highlights – Full Year 2020 Strong growth in OTC, Oral Care and Wound Care 36 Key Drivers of Operational Performance1 OTC • Growth driven by U.S. COVID-19 enhanced demand for TYLENOL in the pain category, U.S. ZYRTEC, U.S. PEPCID due to competitive withdrawal, and NICORETTE, partially offset by OUS declines due to COVID-19 and low incidence of cough and flu Skin Health/ Beauty • Decline driven by COVID-19 impacts and SKU rationalization; partially offset by growth in eCommerce and innovation across brands Oral Care • Growth due to strong performance in LISTERINE® Adult Mouthwash due to U.S. eCommerce and club channel growth, global accelerating category and increased demand attributed to COVID-19, coupled with APAC innovation Baby Care • Decline driven by SKU rationalization, negative COVID-19 impacts OUS, and the divestiture of Baby Center partially offset by AVEENO baby strength Women’s Health • Decline driven by COVID-19 and SKU Rationalization across all regions; partially offset by growth in STAYFREE in APAC Wound Care/Other • Growth driven by strong performance of BAND-AID® Brand Adhesive Bandages, NEOSPORIN and Isopropyl Alcohol in APAC due to COVID-19 Adjusted Operational Sales2: WW 3.1%, U.S. 9.5%, Int’l (1.5)% Additional shipping days contributed ~1% to WW growth Reported: WW 1.1%, U.S. 9.0%, Int’l (4.6)% Operational1: WW 3.0%, U.S. 9.0%, Int’l (1.3)% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding 8.5%, 9.4% -- 36 of 38 -- Key Drivers of Operational Performance1 Immunology • Growth driven by strong uptake of STELARA in Crohn’s Disease and TREMFYA in Psoriasis, share growth of SIMPONI ARIA, and U.S. immunology market growth • REMICADE decline due to increased discounts/rebates and biosimilar competition Infectious Diseases • Share and volume growth of SYMTUZA and JULUCA, partially offset by increased competition for PREZISTA/PREZCOBIX/REZOLSTA and PREZISTA OUS LOE Neuroscience • Paliperidone long-acting injectables growth due to strength of INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA from new patient starts and persistency, partially offset by cannibalization of RISPERDAL CONSTA and declines in CONCERTA due to generic entrants Oncology • DARZALEX continued strong market growth and share gains globally, driven by patient uptake in all lines of therapy and the launch of a subcutaneous formulation in the U.S. and EU • Strong sales of IMBRUVICA due to market growth globally and maintaining a strong share leadership position in all key indications • Growth in ERLEADA driven by launch uptake and share gains • Lower sales of ZYTIGA due to generic competition in the U.S., partially offset by continued strength in the EU • Lower sales of VELCADE due to generic competition Cardiovascular/ Metabolism/ Other (CVM/Other) • Lower sales of PROCRIT/EPREX due to biosimilar competition • Growth in XARELTO due to demand strength, partially offset by higher rebates • INVOKANA/INVOKAMET growth driven by market growth and favorable channel mix in the U.S. as well as gains in the EU, partially offset by U.S. share declines due to competitive pressures Pulmonary Hypertension (PH) • Growth driven by strong sales of OPSUMIT and UPTRAVI due to continued share gains and market growth Adjusted Operational Sales2: WW 8.4%, U.S. 7.8%, Int’l 9.1% Additional shipping days contributed ~1% to WW growth Immunology $15,055 Infectious Diseases $3,574 Neuroscience $6,548 Oncology $12,367 CVM/Other $4,878 PH $3,148 $45,572 8.0%, 8.2% WW Sales $MM 3.5%, 3.9% (6.0)%, (5.7)% 4.7%, 5.2% 7.9%, 8.2% 20.0%, 20.0% 15.7%, 15.8% ■ Reported Growth ■ Operational Growth1 Pharmaceutical Highlights – Full Year 2020 Market leading performance despite the impacts of COVID-19 37 Reported: WW 8.0%, U.S. 7.8%, Int’l 8.3% Operational1: WW 8.2%, U.S. 7.8%, Int’l 8.8% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding -- 37 of 38 -- Orthopaedics $7,763 Surgery $8,232 Vision $3,919 Interventional Solutions $3,046 $22,959 (11.6)%, (11.4)% (12.2)%, (12.3)% 1.6%, 1.3% (15.2)%, (15.1)% (13.4)%, (12.8)% WW Sales $MM ■ Reported Growth ■ Operational Growth1 Medical Devices Highlights – Full Year 2020 Decline driven by negative impacts of COVID-19 on Global Medical Device Markets 38 Reported: WW (11.6)%, U.S. (10.9)%, Int’l (12.2)% Operational1: WW (11.4)%, U.S. (10.9)%, Int’l (11.8)% Key Drivers of Operational Performance1 Interventional Solutions • Electrophysiology growth driven by Atrial Fibrillation share gains and market recovery coupled with strong THERMOCOOL SMARTTOUCH SF Contact Force Sensing Catheter and diagnostic catheter sales offsetting negative impacts from COVID-19 Orthopaedics • Hips: Decline due to the negative impacts of COVID-19 partially offset by leadership position in the anterior approach and related strong market demand for the ACTIS stem and the KINCISE surgical automated system • Knees: Due to negative impact of COVID-19 • Trauma: Market impacted by COVID-19 partially offset by uptake of new products • Spine & Other: Market impacted by COVID-19, partially offset by new products • Spine: WW: ~(14)%, U.S. ~(12)%, OUS: ~(16)% Surgery • Advanced: • Endocutters: ~(9)% primarily due to negative impacts of COVID-19, partially offset by continued success of new products primarily in APAC. • Biosurgery: ~FLAT; Share gains & market growth due to new products and a recovery from a prior year supply disruption in the U.S. offsetting negative impacts from COVID-19 • Energy: ~(9)% primarily due to negative impacts of COVID-19 and competitive pressure in the U.S., partially offset by success of new products primarily in APAC • General: Decline primarily due to negative impacts of COVID-19 coupled with the ASP divestiture and an unfavorable prior period pricing adjustment in the U.S. Vision • Contact Lenses/Other: Impact of COVID-19 and decreases in US and APAC stocking partially offset by continued success of lenses in the ACUVUE OASYS family • Surgical: Driven by negative impacts of COVID-19. Adjusted Operational Sales2: WW (10.5)%, U.S. (10.2)%, Int’l (10.9)% Additional shipping days contributed ~1% to WW growth 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding -- 38 of 38 --